Pfizer's Weekly Haemophilia Drug Backed for NHS Use

Pfizer's weekly haemophilia drug backed for NHS use

Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS - Pharmafile

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi ®  (marstacimab) as an option for preventing bleeding episodes in people 12 years of age and older, weighing at least 35 kg, with severe haemophilia B (congenital factor IX [9] deficiency, factor […] The post NICE recommends Pfizer’s new once-weekly treatment for ha…

NICE recommends Pfizer once-weekly treatment for haemophilia B on NHS

Pfizer announced that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab) as an option for preventing bleeding episodes in people with severe haemophilia B.